What is Mycometrics?
Operating as a specialized microbiology laboratory, Mycometrics provides critical diagnostic services focused on the identification of fungi and bacteria across diverse environmental settings. The company has carved out a distinct market position through its proprietary testing methodologies, including the Environmental Relative Moldiness Index (ERMI) and the Health Effects Roster of Type-Specific Mold and Mycotoxin (HERTSMI) assessments. Beyond its laboratory services, Mycometrics maintains a consumer-facing product line, offering nasal cleanse kits and specialized rinse solutions designed to support respiratory health. This dual-pronged business model allows the firm to bridge the gap between high-precision environmental diagnostics and accessible health maintenance tools, catering to both professional remediation experts and individual consumers seeking to mitigate biological hazards in their living spaces.
How much funding has Mycometrics raised?
Mycometrics has raised a total of $326K across 2 funding rounds:
Debt
$150K
Debt
$176K
Debt (2020): $150K with participation from PPP
Debt (2021): $176K led by PPP
Key Investors in Mycometrics
PPP
Public-Private Partnership
What's next for Mycometrics?
With the recent infusion of capital, Mycometrics is well-positioned to scale its laboratory infrastructure and enhance its diagnostic throughput. The company's focus on late-stage growth suggests a strategic pivot toward expanding its service reach and potentially diversifying its product portfolio to address emerging environmental health concerns. By optimizing its testing workflows and investing in advanced identification technologies, Mycometrics aims to maintain its competitive edge in the microbiology testing market. Future initiatives will likely prioritize the integration of automated data analysis to improve turnaround times for clients, further cementing the company's reputation for accuracy and reliability in the environmental health space.
See full Mycometrics company page
